Accuray Incorporated
ARAY
$0.986 -3.38%
Exchange: NASDAQ | Sector: Healthcare | Industry: Medical Devices
Q4 2024
Published: Sep 19, 2024

Earnings Highlights

  • Revenue of $134.29M up 13.5% year-over-year
  • EPS of $0.03 increased by 227.8% from previous year
  • Gross margin of 28.6%
  • Net income of 3.39M
  • "β€œrecord number of system shipments within the quarter, representing 20% more than our previous highest shipment milestone”" - Suzanne Winter
ARAY
Accuray Incorporated

Executive Summary

In Q4 FY2024, Accuray reported a fifth consecutive quarter of revenue growth, delivering $134.3 million in net revenue, up 14% year over year and representing the highest quarterly revenue in the company’s history. The quarter featured a record 36 system shipments, 28% year-over-year product revenue growth, and a book-to-bill ratio of 1.2, underscoring durable demand across international markets and the momentum of next-generation platforms. Management highlighted meaningful progress in China with the Tomo C program advancing to Type B shipments following final approvals, and a broader push into emerging markets such as APAC and Latin America. Despite near-term margin headwinds from China margin deferral timing, FX effects (notably in Japan) and a supplier quality issue in Q4, Accuray exited the quarter with a positive operating trajectory and a clearly defined path to margin recovery.

Key Performance Indicators

Revenue
Increasing
134.29M
QoQ: 32.79% | YoY: 13.52%
Gross Profit
Increasing
38.45M
28.63% margin
QoQ: 32.26% | YoY: 2.05%
Operating Income
Increasing
6.82M
QoQ: 249.43% | YoY: 1 591.68%
Net Income
Increasing
3.39M
QoQ: 153.41% | YoY: 232.51%
EPS
Increasing
0.03
QoQ: 153.21% | YoY: 227.82%

Revenue Trend

Margin Analysis

Historical Earnings Comparison

PeriodRevenue ($M)EPS ($)YoY GrowthReport
Q3 2025 113.24 -0.02 +12.0% View
Q2 2025 116.17 0.02 +8.3% View
Q1 2025 101.55 -0.04 -2.3% View
Q4 2024 134.29 0.03 +13.5% View
Q3 2024 101.13 -0.06 -14.3% View